Publications by authors named "Miaochen Zhu"
Article Synopsis
- PARP inhibitors are medicine used to treat ovarian cancer, but lots of patients don't respond well to them.
- A study found that adding progesterone to a drug called niraparib can help kill ovarian cancer cells better.
- This combination of drugs could improve treatment results and help doctors predict who will respond well to PARP inhibitors in patients.
Article Synopsis
- High-grade serous ovarian carcinoma (HGSOC) is a really serious type of cancer that affects women and is hard to prevent.
- Researchers found that a hormone called progesterone can help stop this cancer from happening and spreading.
- The study showed that progesterone works better in certain models and may encourage cancer cells to die, showing promise for using it as a way to prevent this disease.
This study aimed to investigate the relationship between promoter methylation () level and radiosensitivity of cervical cancer and its biological basis. This was a prospective multicenter clinical study, comprising two independent cohorts of locally advanced cervical cancer patients. Exfoliated cervical cells were collected at 0, 24, 30, 36, 48, and 64 Gy to test levels.
View Article and Find Full Text PDFBackground: Tumor cell metabolic reprogramming is crucial for the malignant behavior of cancer cells by promoting their proliferation. However, little is known on how transient receptor potential 7 (TRPM7) modulates metabolic reprogramming in ovarian cancer.
Methods: The effects of TRPM7 silencing on transcriptome profile, glucose uptake, lactic acid production, extracellular acidification rate (ECAR), oxygen consumption rate (OCR), intracellular ROS and ATP levels, and NAD+/NADH ratios in ovarian cancer cells were examined.
Objectives: Accurate prediction of prognosis will help adjust or optimize the treatment of cervical cancer and benefit the patients. We aimed to investigate the incremental value of radiomics when added to the FIGO stage in predicting overall survival (OS) in patients with cervical cancer.
Methods: This retrospective study included 106 patients with cervical cancer (FIGO stage IB1-IVa) between October 2017 and May 2019.
Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
June 2021
Ovarian cancer is a common malignant tumor in gynaecology and its mortality rate is the highest in gynecological cancer. Ovarian cancer patients should face platinum resistance, caused by multiple recurrences. According to the platinum-free interval (PFI), recurrent ovarian cancer can be divided into platinum-resistant (PFI<6 months) and platinum-sensitive (PFI≥6 months).
View Article and Find Full Text PDF